Repare <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Initial Data from Phase 1 LIONS Trial of First-in-Class PLK4 Inhibitor RP-1664 in Advanced Solid Tumors
Repare Therapeutics Inc. has announced that it will present initial topline safety, tolerability, and early efficacy data from its Phase 1 LIONS clinical trial at the 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, scheduled for October 22-26, 2025, in Boston, MA. The LIONS trial (NCT06232408) is a first-in-human, multicenter, open-label Phase 1 study evaluating RP-1664, a potential first-in-class, highly selective oral PLK4 inhibitor, as monotherapy in adult and adolescent patients with TRIM37-high solid tumors. The data will be shared in a poster presentation on October 25, 2025, and a copy of the poster will be available on the Repare Therapeutics website at the start of the session.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Repare Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251013080571) on October 13, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。